A Study of Oral Venetoclax Tablets and Oral Azacitidine Versus Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy (VIALE-M)
Acute Myeloid Leukemia (AML)
About this trial
This is an interventional treatment trial for Acute Myeloid Leukemia (AML) focused on measuring Acute myeloid leukemia (AML), Venetoclax, Azacitidine, CC-486, Maintenance Therapy, Conventional Chemotherapy, Best supportive care (BSC)
Eligibility Criteria
Inclusion Criteria:
- Diagnosis of newly diagnosed acute myeloid leukemia (AML).
Participant meets the following disease activity criteria:
- Confirmation of AML by World Health Organization (WHO) criteria (2016) and have confirmed complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following completion of intensive induction and consolidation chemotherapies.
- Achieved first CR + CRi within 120days of first dose of study drug or be no more than 75 days since last dose of intensive conventional chemotherapies.
- AML has intermediate or poor risk cytogenetics per National Comprehensive Cancer Network (NCCN) 2016 criteria.
- Eastern Cooperative Oncology Group (ECOG) performance status <= 2.
- Participant must have adequate hematologic, renal, and liver function laboratory values as described in the protocol.
Exclusion Criteria:
- History of acute promyelocytic leukemia (APL).
- History of active central nervous system involvement with acute myeloid leukemia (AML).
Sites / Locations
- Mitchell Cancer Institute /ID# 216443
- Compassionate Cancer Care Research Group - Fountain Valley /ID# 216156
- University of California, Los Angeles /ID# 219149
- Colorado Blood Cancer Institute /ID# 214280
- St. Alphonsus Regional Medical /ID# 216424
- Rush University Medical Center /ID# 218815
- University of Kentucky Markey Cancer Center /ID# 215048
- Norton Cancer Institute /ID# 216401
- Tulane Medical Center - New Orleans /ID# 218166
- Ochsner Clinic Foundation-New Orleans /ID# 214583
- Tufts Medical Center /ID# 216110
- Massachusetts General Hospital /ID# 217307
- UMass Chan Medical School /ID# 218163
- Saint Louis University Cancer Center /ID# 218164
- Oncology Hematology Associates (OHA) - Springfield /ID# 216351
- The John Theurer Cancer /ID# 215191
- Rutgers Cancer Institute of New Jersey /ID# 239708
- Weill Cornell Medical College /ID# 214847
- Providence Portland Medical Ct /ID# 216231
- Fox Chase Cancer Center /ID# 239372
- UPMC Hillman Cancer Ctr /ID# 214051
- Prisma Health Cancer Institute-Faris Road /ID# 216066
- St Francis Cancer Center /ID# 216115
- Gibbs Cancer Center & Research /ID# 216192
- Tennessee Oncology-Nashville Centennial /ID# 218757
- Texas Oncology- Baylor Charles A. Sammons Cancer Center /ID# 214584
- University of Texas MD Anderson Cancer Center /ID# 225201
- St George Hospital /ID# 215416
- Liverpool Hospital /ID# 215415
- Shoalhaven District Memorial Hospital /ID# 221973
- Wollongong Hospital /ID# 216071
- Gold coast University Hospital /ID# 214650
- Toowoomba Hospital /ID# 217922
- Princess Alexandra Hospital /ID# 238753
- Royal Adelaide Hospital /ID# 238754
- Box Hill Hospital /ID# 217622
- Barwon Health /ID# 217921
- Perth Blood Institute Ltd /ID# 217531
- Tom Baker Cancer Centre /ID# 214625
- University of Alberta Hospital - Division of Hematology /ID# 215656
- Juravinski Cancer Centre /ID# 214623
- London Health Sciences Center- University Hospital /ID# 216055
- Ottawa Hospital Research Institute /ID# 214627
- Princess Margaret Cancer Centre /ID# 214624
- McGill University Health Center Research Institute /ID# 215984
- Beijing Friendship Hospital /ID# 216455
- Chinese PLA General Hospital /ID# 216286
- Guangdong Provincial People's Hospital /ID# 216284
- Nanfang Hospital of Southern Medical University /ID# 215565
- Henan Cancer Hospital /ID# 215566
- Union Hospital Tongji Medical College Huazhong University of Science and Technol /ID# 218046
- Tongji Hospital Tongji Medical College of HUST /ID# 216456
- Tangdu Hospital of The Fourth Military Medical University, PLA /ID# 216283
- Shanghai Tongji Hospital /ID# 218800
- West China Hospital, Sichuan University /ID# 216606
- Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sc /ID# 215558
- The First Affiliated Hospital, Zhejiang University School of Medicine /ID# 215564
- Peking University International Hospital /ID# 217439
- Fakultni Nemocnice Brno /ID# 214807
- Fakultni nemocnice Ostrava /ID# 214809
- Ustav hematologie a krevni transfuze /ID# 215137
- CHU de Nice - Hôpital Archet 1 /ID# 217368
- CHU Bordeaux - Hopital Haut Leveque /ID# 215150
- CHRU Lille - Hopital Claude Huriez /ID# 217474
- Hopital Avicenne - APHP /ID# 215152
- CHRU Tours - Hopital Bretonneau /ID# 216186
- CHU de Nantes - Hotel Dieu /ID# 217367
- Centre Hospitalier de la Cote Basque /ID# 216185
- Centre Hospitalier du Mans /ID# 215148
- Institut Gustave Roussy /ID# 215158
- Chu Angers /Id# 215151
- Hopital Henri Mondor /ID# 215159
- Centre Hospitalier de Versailles André Mignot /ID# 215157
- Universitaetsklinikum Leipzig /ID# 214440
- Universitaetsklinikum Schleswig-Holstein Campus Luebeck /ID# 215173
- Klinikum Chemnitz gGmbH /ID# 216073
- Universitaetsklinikum Halle (Saale) /ID# 221109
- Universitaetsklinikum Giessen und Marburg /ID# 214734
- General Hospital of Athens Laiko /ID# 213869
- University General Hospital Attikon /ID# 214298
- University General Hospital of Heraklion PA.G.N.I /ID# 214075
- General University Hospital of Alexandroupolis /ID# 213870
- General Hospital of Athens Evaggelismos and Ophthalmiatrio of Athens Polyclinic /ID# 213872
- University General Hospital of Patras /ID# 213871
- Debreceni Egyetem Klinikai Kozpont /ID# 214422
- Somogy Varmegyei Kaposi Mor Oktato Korhaz /ID# 214426
- Szabolcs-Szatmar-Bereg Varmegyei Oktatokorhaz /ID# 214425
- Markusovszky Egyetemi Oktatokorhaz /ID# 215644
- Semmelweis Egyetem /ID# 214423
- Tel Aviv Sourasky Medical Center /ID# 239698
- Hadassah Medical Center-Hebrew University /ID# 239700
- Shaare Zedek Medical Center /ID# 239699
- Rabin Medical Center /ID# 239696
- Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona /ID# 213944
- IRCCS Azienda Ospedaliero-Universitaria di Bologna /ID# 213948
- ASST Spedali civili di Brescia /ID# 214580
- A.O.U. Policlinico G. Rodolico S.Marco- Presidio G.Rodolico /ID# 214802
- ASST Grande Ospedale Metropolitano Niguarda /ID# 213946
- Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico /ID# 214826
- Azienda Ospedaliera di Rilievo Nazionale Antonio Cardarelli /ID# 213947
- Azienda Ospedaliera Universitaria Federico II /ID# 214278
- Ospedale S.Eugenio /ID# 214277
- A.O.U. Citta della Salute e della Scienza di Torino /ID# 214505
- Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital /ID# 215680
- Aichi Cancer Center Hospital /ID# 215284
- University of Fukui Hospital /ID# 215283
- National Hospital Organization Kyushu Cancer Center /ID# 214841
- Kyushu University Hospital /ID# 215286
- Hokkaido University Hospital /ID# 215938
- National Hospital Organization Mito Medical Center /ID# 214699
- Tohoku University Hospital /ID# 214669
- Nagasaki University Hospital /ID# 214916
- Okayama University Hospital /ID# 214840
- Osaka Metropolitan University Hospital /ID# 215225
- Kindai University Hospital /ID# 214915
- Saitama Medical University International Medical Center /ID# 214823
- NTT Medical Center Tokyo /ID# 214959
- Yamagata University Hospital /ID# 214698
- Seoul National University Bundang Hospital /ID# 215549
- Pusan National University Hospital /ID# 213941
- Seoul National University Hospital /ID# 213943
- Samsung Medical Center /ID# 213940
- Pan American Center for Oncology Trials, LLC /ID# 214953
- Nizhny Novgorod Regional Clinical Hospital named N.A. Semashko /ID# 214309
- Academician I.P. Pavlov First St. Petersburg State Medical University /ID# 215393
- P. Hertsen Moscow Oncology Research Institute /ID# 214312
- MMCC Kommunarka /ID# 215223
- Clinic of Immunopathology, SRIFCI /ID# 217937
- Almazov National Medical Research Centre /ID# 214306
- Regional Clinical Hospital of Yaroslavl /ID# 214318
- Instituto Catalan de Oncologia (ICO) L'Hospitalet /ID# 214715
- Hospital Universitario de Navarra /ID# 214788
- Hospital Santa Creu i Sant Pau /ID# 214714
- Hospital Universitario Reina Sofia /ID# 214786
- Hospital Universitario Infanta Leonor /ID# 214843
- MD Anderson Madrid /ID# 214477
- Hospital Universitario Ramon y Cajal /ID# 214684
- Hospital Universitario Fundacion Jimenez Diaz /ID# 214933
- Hospital Universitario 12 de Octubre /ID# 214789
- Hospital Universitario Virgen de la Victoria /ID# 214713
- Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 213953
- China Medical University Hospital /ID# 213952
- National Taiwan University Hospital /ID# 213939
- Linkou Chang Gung Memorial Hospital /ID# 213951
- Erciyes University Medical Fac /ID# 214240
- Gulhane Askeri Tip Academy /ID# 214242
- Ankara Univ Medical Faculty /ID# 214239
- Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty /ID# 215525
- Karadeniz University /ID# 214241
- University Hospitals Bristol /ID# 215911
- Leicester Royal Infirmary /ID# 215924
- Barts Health NHS Trust /ID# 215909
- Guys and St Thomas NHS Foundation Trust /ID# 215908
- Cardiff & Vale University Health Board /ID# 215906
- University Hospitals Birmingham NHS Foundation Trust /ID# 215910
- University College London Hospitals NHS Foundation Trust /ID# 215921
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Experimental
Part 1: Dose Confirmation
Part 3 (Dose Finding): Dose Escalation
Part 3 (Dose Finding): Safety Expansion
Participants will receive venetoclax once daily (QD) (Days 1-28) for up to 48 cycles, azacitidine (AZA) QD on Days 1-5 of each 28 day cycle for up to 6 cycles.
Participants will receive venetoclax QD for up to 24 cycles, CC-486 QD on Days 1 to 14 of each 28-day cycle for up to 24 cycles to determine recommended phase 3 dose (RPTD).
Participants will receive venetoclax QD for up to 24 cycles, CC-486 QD on Days 1 to 14 of each 28-day cycle for up to 24 cycles at the RPTD.